A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

PHASE2CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

May 3, 2022

Study Completion Date

August 2, 2023

Conditions
Pan Tumor
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

Trial Locations (60)

1090

Local Institution - 0112, Brussels

1199

Local Institution - 0078, CABA

1200

Local Institution - 0113, Brussels

1280

Local Institution - 0087, Ciudad Autónoma de Buenos Aires

1426

Local Institution - 0015, CABA

1431

Local Institution - 0016, Ciudad Autonoma Beunos Aires

2010

Local Institution - 0062, Sydney

2065

Local Institution - 0118, St Leonards

2100

Local Institution - 0080, Copenhagen

2730

Local Institution - 0081, Herlev

3000

Local Institution - 0114, Leuven

4102

Local Institution - 0117, Woolloongabba

5000

Local Institution - 0119, Córdoba

12200

Local Institution - 0039, Berlin

13273

Local Institution - 0075, Marseille

13790

Broome Oncology, Johnson City

16132

Local Institution - 0032, Genova

20133

IRCCS Istituto Nazionale Tumori Milano, Milan

27710

Duke Cancer Institute, Durham

28041

Local Institution - 0083, Madrid

31008

Local Institution - 0110, Pamplona

31100

Local Institution - 0074, Toulouse

45147

Local Institution - 0086, Essen

53100

Local Institution - 0031, Siena

53127

Local Institution - 0001, Bonn

55404

Local Institution - 0093, Minneapolis

69373

Local Institution - 0072, Lyon

75231

Local Institution - 0094, Dallas

75248

Local Institution - 0073, Paris

75702

Texas Oncology - Northeast Texas, Tyler

77030

Local Institution - 0090, Houston

78731

Local Institution - 0095, Austin

80131

Local Institution - 0029, Napoli

80218

Rocky Mountain Cancer Centers, Denver

90404

John Wayne Cancer Center, Santa Monica

94805

Local Institution - 0085, Villejuif

97080

Local Institution - 0043, Würzburg

97239

Local Institution - 0079, Portland

117599

Local Institution - 0066, Singapore

168583

Local Institution - 0065, Singapore

200542

Local Institution - 0067, Craiova

300239

Local Institution - 0071, Timisoara, Timis

400015

Local Institution - 0068, Cluj-Napoca

407280

Local Institution - 0070, Floreşti

8330024

Local Institution - 0018, Santiago

8420383

Local Institution - 0082, Santiago

T6G 1Z2

Local Institution - 0010, Edmonton

L8V 5C2

Local Institution - 0060, Hamilton

H2X 3E4

Local Institution - 0036, Montreal

H3T 1E2

Local Institution - 0088, Montreal

01307

Local Institution - 0002, Dresden

3015 GD

Local Institution - 0116, Rotterdam

1066 CX

Local Institution - 0115, Amsterdam

02-781

Local Institution - 0076, Warsaw

80-214

Local Institution - 0077, Gdansk

00927

Fundacion De Investigacion, San Juan

022328

Local Institution - 0069, Bucharest

08035

Local Institution - 0084, Barcelona

W12 OHS

Local Institution - 0106, London

PR2 9HT

Local Institution - 0107, Preston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY